Last reviewed · How we verify
CVL237 tablets
CVL237 tablets are a small molecule that targets the SGLT2 receptor.
CVL237 tablets are a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.
At a glance
| Generic name | CVL237 tablets |
|---|---|
| Sponsor | Convalife (Shanghai) Co., Ltd. |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 2 |
Mechanism of action
By inhibiting the SGLT2 receptor, CVL237 tablets reduce glucose reabsorption in the kidneys, thereby lowering blood glucose levels. This mechanism is particularly useful in the treatment of type 2 diabetes. CVL237 tablets have shown promise in phase 2 clinical trials for this indication.
Approved indications
- Type 2 diabetes
Common side effects
- Nausea
- Diarrhea
- Vomiting
Key clinical trials
- A Single-arm, Open-label, Multicenter, Phase Ib/II Clinical Trial of CVL237 Tablets in Combination With Serplulimab Injection for the Treatment of Advanced Solid Tumors With PTEN Loss or Low Expression (PHASE2)
- CVL237 Tablets for APDS/PASLI (PHASE2, PHASE3)
- CVL237 Tablets in the Treatment of Advanced Solid Tumors With PTEN Deficiency (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CVL237 tablets CI brief — competitive landscape report
- CVL237 tablets updates RSS · CI watch RSS
- Convalife (Shanghai) Co., Ltd. portfolio CI